Skip to main content
OpenTrials

Clinical trial condition

Carbohydrate Metabolism, Inborn Errors

Explore clinical trials studying Carbohydrate Metabolism, Inborn Errors. Study availability and eligibility vary by location and protocol.

544 public trials 96 recruiting studies
Refine in advanced search Browse all conditions

Carbohydrate Metabolism, Inborn Errors trial results

Completed

A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

NCT00077662

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +12 more
Locations
  • Children's Hospital Medical Center Washington D.C., District of Columbia, United States
  • School of Medicine, Campus Box 8111 St Louis, Missouri, United States
  • Children's Hospital & Regional Medical Center Seattle, Washington, United States
  • Institut de Myologie, Groupe Hospitalier Pitie-Salpetriere, Batimant Babinski Paris, France
View Trial Details
Completed

Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

NCT00113035

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +13 more
Locations
  • Tower Hematology/Oncology Medical Group Beverly Hills, California, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Washington University Medical Center St Louis, Missouri, United States
  • Mount Sinai School of Medicine New York, United States
View Trial Details
Completed

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

NCT00158600

Conditions
Acid Maltase Deficiency Disease, Brain Diseases, Brain Diseases, Metabolic, +16 more
Locations
  • Tower Hematology Oncology Medical Group Beverly Hills, California, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Washington University Medical Center St Louis, Missouri, United States
  • Mount Sinai School of Medicine New York, United States
View Trial Details
Completed

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

NCT00144781

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +12 more
Locations
  • Hospital Infantil Joana de Gusmao Florianópolis, Santa Catarina, Brazil
  • Universidade Federal de Minas Gerais Belo Horizonte, Brazil
  • Hospital de Clinical de Porto Alegre Porto Alegre, Brazil
  • Universidade Federal de Sao Paulo São Paulo, Brazil
View Trial Details
Completed

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

NCT00146757

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +12 more
Locations
  • Hôpital E. Herriot Lyon, France
  • Johannes Gutenberg Universität Kinderklinik, Mainz, Germany
  • Sophia Children's Hospital Rotterdam, Netherlands
  • Willink Biochemical Genetics Unit Royal Hospital for Children Manchester, United Kingdom
View Trial Details
Completed

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

NCT00146770

Conditions
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +12 more
Locations
  • University of South Alabama Mobile, Alabama, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
  • University of Rochester Rochester, New York, United States
  • University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
View all 25 locations
View Trial Details

Related conditions